Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: A focus on chemically-modified curcumins

Current Medicinal Chemistry

Volumn 19, Issue 25, 2012, Pages 4348-4358

  Zhang, Yu ^a   Gu, Ying ^a   Lee, Hsi Ming ^a   Hambardjieva, Elena ^b   Vranková, Kveta ^b   Golub, Lorne M ^a   Johnson, Francis ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Chemically modified curcumin; Connective tissue degradation; Enolic diketone moiety; Matrix metalloproteinases; Zinc binding

Indexed keywords

1,7 BIS PHENYL 4 METHOXYCARBONYLHEPTA 1E,6E DIEN 3,5 DIONE; 1,7 BIS(2 HYDROXYPHENYL) 4 METHOXYCARBONYLHEPTA 1E,6E DIEN 3,5 DIONE; 1,7 BIS(3 HYDROXYPHENYL) 4 METHOXYCARBONYLHEPTA 1E,6E DIEN 3,5 DIONE; 1,7 BIS(3 NITRO 4 HYDROXY 5 METHOXYPHENYL) 4 METHOXYCARBONYLHEPTA 1E,6E DIEN 3,5 DIONE; 1,7 BIS(3 PYRIDYL) 4 METHOXYCARBONYLHEPTA 1E,6E DIEN 3,5 DIONE; 1,7 BIS(3 PYRIDYL) HEPTA 1E,6E DIEN 3,5 DIONE; 1,7 BIS(4 ACETOXY 3 METHOXYPHENYL) 4 METHOXYCARBONYLHEPTA 1E,6E DIEN 3,5 DIONE; 1,7 BIS(4 HYDROXY 3 METHOXYPHENYL) 4 METHOXYCARBONYLHEPTA 1E DIEN 3,5 DIONE; 1,7 BIS(4 HYDROXY 3,5 DIMETHOXYPHENYL) 4 METHOXYCARBONYLHEPTA 1E,6E DIEN 3,5 DIONE; 1,7 BIS(4 HYDROXYPHENYL) 4 METHOXYCARBONYLHEPTA 1E,6E DIEN 3,5 DIONE; 1,7 BIS(4 N,N DIMETHYLAMINOPHENYL)HEPTA 1E,6E DIEN 3,5 DIONE; 1,7 BIS[[4 (4 METHYLPIPERAZINYL 1 YL)PHENYL]] 4 METHOXYCARBONYLHEPTA 1E,6E DIEN 3,5 DIONE; 1,7 DIPHENYL HEPTA 1E,6E DIEN 3,5 DIONE; CURCUMIN; DIDEMETHOXYCURCUMIN; LEAD; MATRIX METALLOPROTEINASE INHIBITOR; PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; IN VITRO STUDY; MALE; NONHUMAN; PERITONEUM MACROPHAGE; RAT; STRUCTURE ACTIVITY RELATION; ZYMOGRAPHY;

ANIMALS; CELL LINE; CELLS, CULTURED; CURCUMIN; DIABETES MELLITUS, TYPE 1; DRUG DESIGN; HUMANS; MACROPHAGES, PERITONEAL; MALE; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84866639683     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712802884295     Document Type: Article

References (49)

1. Gross, J.; Lapiere, C.M. Collagenolytic activity in amphibian tissues -a tissue culture assay. Proc. Natl. Acad. Sci. U.S.A., 1962, 48, 1014-1022
2. Visse R.; Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res., 2003, 92, 827-839
3. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors. Chem. Rev., 1999, 99, 2735-2776
4. Peterson, J.T. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res., 2006, 69, 677-687.
5. Golub, L.M.; Greenwald, R.A.; Ramamurthy, N.S.; McNamara, T.F.; Rifkin, B.R. Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs. Crit. Revs. Oral Biol. Med., 1991, 2, 297-322
6. Peterson, J.T. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardio. Res., 2006, 69, 677-687
7. Golub, L.M.; Wolff, M.; Roberts, S.;Lee, H.M.; Leung, M.; Payonk, G.S. Treating periodontal diseases by blocking tissue-destructive enzymes. J Am Dent Assoc., 1994, 125, 163-169
8. Golub, L.M.; Lee, H.M.; Lehrer, G.; Nemiroff, A.; McNamara, T.F.; Kaplan, R.; Ramamurthy, N.S. Minocycline reduces gingival collagenolytic activity during diabetes: Preliminary observations and a proposed new mechanism of action. J. Periodont. Res., 1983, 18, 516-526
9. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science, 2002, 295, 2387-2392
10. Overall, C. M.; Lopez-Otin, C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Rev. Cancer, 2002, 2, 657-672
11. Sorsa T.; Tjäderhane L.; Konttinen Y.T.; Lauhrio A.; Salo, T.; Lee, H.M.; Golub, L.M.; Brown, D.L.; Mäntylä, P. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment for periodontal inflammation. Ann. Med., 2006, 38, 306-321
12. Golub, L.M.; Lee, H.M.; Ryan, M.E.; Giannobile, W.V.; Payne, J.; Sorsa, T. Tetracyclines Inhibit Connective Tissue Breakdown by Multiple Non-Antimicrobial Mechanisms. Adv. Dent. Res., 1998, 12, 12-26
13. Dezube, B.J.; Krown, S.E.; Lee, J.Y.; Bauer, K.S.; Aboulafia, D.M. Randomized Phase II Trial of Matrix Metalloproteinase Inhibitor COL-3 in AIDSRelated Kaposi's Sarcoma: An AIDS Malignancy Consortium Study. Journal of Clinical Oncology, 2006, 24, 1389-1394
14. Richards, C.; Pantanowitz, L.; Dezube, B.J. Antimicrobial and nonantimicrobial tetracyclines in human cancer trials. Pharmacological Research, 2011, 63, 151-156
15. Sandberg, S.; Glette, J.; Hopen, G.; Solberg, C.O. Doxycycline induced photodamage to human neutrophils and tryptophan. Photochem Photobiol., 1984, 39, 43-48
16. Riaz, M.; Pilpel, N. Effects of ultraviolet light on lecithin monolayers in the presence of fluorescein dyes and tetracycline drugs. J Pharm Pharmacol., 1983, 35, 215-218
17. Bachmeier, B.E.; Mohrenz, I.V.; Mirisola, V.; Schleicher, E.; Romeo, F.; Höhneke, C.; Jochum, M.; Nerlich, A.G.; Pfeffer, U. Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkB. Carcinogenesis, 2008, 29, 779-789
18. Kaur, G.; Tirkey, N.; Bharrhan, S.; Chanana, V.; Rishi, P. ; Chopra, K. Inhibition of oxidative stress and cytokine activity by curcumin in amelioration of endotoxin-induced experiemental hepatotoxicity. Clin. Exp. Immunol., 2006, 145, 313-321
19. Begum, A.N. Jones, M.R.; Lim, G.P.; Morihara, T.; Kim, P.;Heath, D.D.; Rock, C.L.; Pruitt, M.A.; Yang F.; Hudspeth, B.; Hu, S.; Faull, K.F.; Teter, B.; Cole, G.M.; Frautschy, S.A. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther., 2008, 326, 196-208
20. Banerji, A.; Chakrabarti, J.; Mitra, A.; Chatterjee, A. Effect of curcumin on gelatinase A (MMP-2) activity in B16F10 melanoma cells. Cancer Lett., 2004, 211, 235-242
21. Woo, M.S.; Jung, S.H.; Kim, S.Y.; Hyun, J.W.; Ko, K.H.; Kim, W.K.; Kim, H.S. Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells. Biochem Biophys Res Commun., 2005, 335, 1017-1025
22. Baum L.; Ng, A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimers Dis., 2004 , 6, 367-377
23. Lampe, V.; Milobedzka, J.; Kostanecki, St. V. Zur Kenntnis des Curcumins. Berichte., 1910, 43, 2163
24. Pabon, H.J.J. A synthesis of curcumin and related compounds. RECUEIL, 1964, 83, 379-386
25. Pedersen, U.; Rasmussen, P.B.; Lawesson, S.O. Synthesis of naturally occurring curcuminoids and related compounds. Liebigs Ann. Chem., 1985, 1557-1569
26. Aggarwal, B.B.; Kumar, A; Bharti, A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res., 2003, 23, 363-398
27. Sharma, O.P. Antioxidant activity of curcumin and related compounds. Biochem. Pharmacol., 1976, 25, 1811-1812
28. Ruby, A.J.; Kuttan, G; Babu, K.D.; Rajasekharan, K.N.; Kuttan, R. Antitumour and antioxidant activity of natural curcuminoids. Cancer Lett., 1995, 94, 79-83
29. Anand, P.; Kunnumakkara, A.B.; Newman, R.A.; Aggarwal, B.B. Bioavailability of Curcumin: Problems and Promises. Molecular Pharmaceutics, 2007, 4, 807-818
30. Cameron, D.W.; Deutscher, D. J.; Feutrill, G.I.; Griffiths, P.G. Chemistry of the Coccoidea. VIII. Synthesis of the ancient dyestuff kermesic acid and of related anthraquinones Australian Journal of Chemistry, 1981 , 34, 2401-2421
31. Buechi, G.; Wuest, H. Synthetic Studies on Damascenones. Helvetica Chimica Acta, 1971, 54, 1767-1775
32. Eckberg, R.P.;Nelson, J.H.; Kenney, J.W.; Howells, P.N.; Henry, R.A.Reactions of bis(2, 4-pentanedionato)nickel(II) with isocyanates and other electrophiles. Electrophilic addition to 2, 4-pentanedione catalyzed by bis(2, 4-pentanedionato)nickel(II). Inorganic Chemistry, 1977, 16, 3128-3129
33. O'Brien, P.M.; Sliskovic, D.R.; Blankley, C. J.; Roth, B.D.; Wilson, M.W.; Hamelehle, K.L.; Krause, B.R.; Stanfield, R.L. Inhibitors of Acyl-CoA:Cholesterol O-Acyl Transferase (ACAT) as Hypocholesterolemic Agents. 8. Incorporation of Amide or Amine Functionalities into a Series of Disubstituted Ureas and Carbamates. Effects on ACAT Inhibition in vitro and Efficacy in vivo. J. Med. Chem., 1994, 37, 1810-1822
34. Nagase, H.; Enghild, J.J.; Suzuki, K.; Salvesen, G. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry, 1990, 29, 5783-5789
35. Nagase, H.; Fields, C.G.; Fields, G.B. Design and Characterization of a Fluorogenic Substrate Selectively Hydrolyzed by Stromelysin 1 (Matrix Metalloproteinase-3). J. Biol. Chem., 1994, 269, 20952-20957
36. Liao, G.J.; Simone, J.; Simon, S.R. Paracrine downregulation of FcrRIII in human monocyte-derived macrophages induced by phagocytosis of nonopsonized particles. Blood, 1994, 83, 2294-2304
37. Brown, D.L.; Desai, K.K.; Vakili, B.A.; Nouneh, C.; Lee, H.M.; Golub, L.M. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 733-738
38. Bingham, S.J.; Tyman, J.H.P. Improved synthesis of alkyl diacetylacetates. Organic Preparations and Procedures INT., 2001, 33, 357-409
39. Knight, C.G.; Willenbrock, F; Murphy, G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett., 1992, 296, 263-266
40. Golub, L.M.; Lee, H.M.; Stoner, J.A.; Sorsa, T.; Reinhardt, R.A.; Wolff, M.S.; Ryan, M.E.; Nummikoski, P.V.; Payne, J.B. Subantimicrobial-dose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women. J Periodontol., 2008, 79, 1409-1418
41. Sugiyama, Y; Kawakishi, S; Osawa, T. Involvement of the -diketone moiety in the antioxidative mechanism of tetrahydrocurcumin. Biochem. Pharmacol. 1996, 52, 519-525
42. Morimoto, T.; Yamasaki, M.; Nakata, K.; Tsuji, M.; Nakamura, H. The expression of macrophage and neutrophil elastases in rat periradicular lesions. J. Endod., 2008, 34, 1072-1076
43. Clemens M.; Kang, D.; Napolitano, N.; Lee, H.M.; Golub, L.M.; Gu, Y. LPS or CRP/oxLDL Cholesterol-Complex: Temporal Study of Cytokine/ MMP Production. J. Dent. Res., 2011, 90, Abstract # 2284
44. Napolitano, N.;Kang, D.; Clemems, M.; Lee, H.M.; Johnson, F.; Golub, L.M.; Gu, Y. Chemically Modified Curcumins Suppress Human Mononuclear Cell Cytokines. J. Dent. Res., 2011, 90, Abstract # 2292
45. Clemens, M.; Napolitano, N.; Lee, H.M.; Zhang, Y.; Johnson, F.; Golub, L.M.; Gu, Y. Chemically modified Curcumin Normalizes Chronic Inflammation in Diabetic Rats. J. Dent. Res., 2012, 91, (spec. issue), Abstract # 1526
46. Napolitano, N.; Clemems, M.; Lee, H.M.; Zhang, Y.; Johnson, F.; Golub, L.M.; Gu, Y. Novel Curcumin Derivatives Suppress Inflammatory Mediators in Periodontally-relevant Cells. J. Dent. Res., 2012, 91, (spec. issue), Abstract # 1527
47. Elburki, M.; Lee, H.M.; Gupta, N.; Balacky, P.; Zhang, Y.; Johnson, F.; Zhang, Y.; Golub, L.M. Chemically-Modified Curcumins Inhibit Alveolar Bone Loss in Diabetic Rats with Periodontitis. J. Dent. Res., 2012, 91, (spec. issue), Abstract # 1528
48. Yu, H.W.; Zhang, Y.; Zhang, Y.; Lee, H.M.; McClain, S.A.; Johnson, F.; Golub, L.M. A Novel Chemicallymodified Curcumin (CMC2.24) Improves Diabetic Wound-Healing. J. Dent. Res., 2012, 91, (spec. issue), Abstract # 1529
49. Katzap, E.; Goldstein, M.J.; Shah, N.V.; Schwartz, J.; Razzano, P.; Golub, L.M.; Johnson, F.; Greenwald, R.; Grande, D. The chondroprotective capability of curcumin (curcuma longa) and its derivatives against IL-1-and OsMmediated chrondrolysis. Trans. Orthoped. Res. Soc., 2011, Abstract # 36.